Efficacy results will be summarized for the overall treatment regimen. Overall safety will be assessed by descriptive analyses using tabulated frequencies of AEs by grade using CTCAE version 4.03 in terms of treatment- emergent AEs, SAEs, and clinically significant changes in safety laboratory tests, physical examinations, ECGs, ECHOs, and vital signs. ORR will be evaluated in accordance with RECIST Version 1.1 and irRC. The percentage of subjects (and 95% confidence interval [CI]) who achieve a confirmed response will be summarized. DCR will be evaluated similar to ORR. PFS, OS, and DOR will be analyzed using Kaplan- Meier methods. Descriptive statistics of PROs will be presen ted. Correlations of tumor molecular profiles, therapy-induced changes in immune responses, and molecular changes in ctDNA and ctRNA with subject outcomes will be explored. NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 2 Confidential and Proprietary 15 Figure 1: Study Treatment Schema NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 2 Confidential and Proprietary 16 Figure 2: Induction Phase Treatment Schema NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT -3.067 Amendment 2 Confidential and Proprietary 17 Figure 3: Maintenance Phase Treatment Schema NANT TNBC Vaccine NantKwest, Inc. Clinical Trial Protocol: QUILT-3.067 Amendment 2 APPENDIX 1. SPONSOR SIGNATURE Study Title: NANT triple negative breast cancer (TNBC) vaccine: molecularly informed integrated immunotherapy combining innate high- affinity natural killer (haNK) cell therapy with adenoviral and yeast-based vaccines to induce T-cell responses in subjects with TNBC who have progressed on or after standard-of-care thera py. Study Number: QUILT-3.067 Version Number: 3 Final Date: 01March2018 This clinical trial protocol was subject to critical review and has been approved by NantKwest.